August 2023

Basal-like triple-negative breast cancer. Oral sunitinib drastically suppressed the basal-like TNBCBasal-like triple-negative breast cancer. Oral sunitinib considerably suppressed the basal-like TNBC OX2 Receptor Formulation development curve of tumor volume in…

Ssays, and quantitative proteomics delivers investigators withOPENCell Death and Differentiation (2014) 21, 491?02 2014 Macmillan Publishers Limited All rights reserved 1350-9047/nature/cddSelective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of…